{"disease":{"id":"castration-resistant-prostatic-cancer","name":"castration resistant prostatic cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03748641","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":765,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04833517","title":"Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Universität des Saarlandes","has_results":false},{"nct_id":"NCT02398526","title":"Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06863272","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06785636","title":"Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Pathos AI, Inc.","has_results":false},{"nct_id":"NCT04126915","title":"Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Yinghao Sun","has_results":false},{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT04381832","title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT03939689","title":"I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Progenics Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04844749","title":"Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Veru Inc.","has_results":false},{"nct_id":"NCT04104607","title":"The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT04249947","title":"P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Poseida Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05293496","title":"A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT03389451","title":"68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Michael Graham PhD, MD","has_results":true},{"nct_id":"NCT04116164","title":"Safety and Targeting of Anti-hk2 Antibody in mCRPC","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"SpectronRX","has_results":false},{"nct_id":"NCT03248570","title":"Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04404140","title":"A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04918810","title":"Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","has_results":false},{"nct_id":"NCT06033001","title":"Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)","phase":"","overall_status":"TEMPORARILY_NOT_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Lantheus Medical Imaging","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}